Core Insights - UCB has selected Georgia for its new $2 billion biologics manufacturing facility, which will be a key part of its global manufacturing infrastructure [1] - The facility will create approximately 330 jobs and is expected to generate $5 billion for Georgia's economy [2] - UCB plans to utilize automation, AI, and robotics to enhance operational efficiency at the site [2] Company Expansion - The Gwinnett County facility will support the production of both recently approved and future pipeline medicines, including three investigational and five marketed biologics [3] - UCB's leading biologic, Bimzelx, generated sales of €2.23 billion ($2.58 billion) in 2025, with projections of $7.5 billion in sales by 2031, primarily from the US market [4] - UCB has a long-standing presence in Georgia, having established its US headquarters in Smyrna over thirty years ago [5] Workforce and Growth - UCB's CEO emphasizes Georgia's strong talent pool and manufacturing legacy as key reasons for the expansion [6] - Since 2017, UCB has increased its American workforce by 73%, currently employing nearly 2,000 individuals in the US [6] Industry Context - UCB's expansion aligns with a broader trend of pharmaceutical companies investing in US manufacturing, driven by government incentives for onshoring production [7]

Core Insights - The top 20 global biopharmaceutical companies saw a 4% increase in combined market capitalisation from $3.7 trillion on June 30, 2025, to $3.8 trillion on September 30, 2025, despite challenges from tariffs and drug pricing pressures [1] Company Performances - UCB experienced the largest market capitalisation growth of 40.9%, reaching $59.8 billion in Q3 2025, driven by the competitive positioning of its drug Bimzelx in hidradenitis suppurativa [2] - Alnylam Pharmaceuticals recorded a 40.6% increase in market capitalisation, attributed to strong sales of its RNAi therapeutic Amvuttra, which saw a 59% quarter-on-quarter increase in global sales to $492 million in Q2 2025 [3] - AbbVie reported a 24.7% rise in market capitalisation, bolstered by its $2.1 billion acquisition of Capstan Therapeutics and plans to invest $195 million in a new manufacturing facility in North Chicago [4] - Johnson & Johnson's market capitalisation grew by 21.5%, supported by a 5.8% sales growth in Q2 and FDA approval of its monoclonal antibody Tremfya for paediatric patients [5]

Core Insights - Oruka Therapeutics is developing ORKA-002, a novel monoclonal antibody with an extended half-life targeting IL-17A/F, which shows potential for less frequent dosing compared to existing therapies [1][3][6] - The half-life of ORKA-002 in non-human primates (NHP) exceeds 30 days, which is over three times longer than bimekizumab, suggesting a dosing interval of two to three times per year [1][6] - ORKA-002 demonstrates equivalent potency to bimekizumab with similar binding affinity, indicating a promising profile for treating chronic skin diseases like plaque psoriasis and psoriatic arthritis [2][3][6] Company Overview - Oruka Therapeutics aims to set a new standard for treating chronic skin diseases, focusing on achieving high rates of complete disease clearance with infrequent dosing [4] - The company is advancing a proprietary portfolio of antibodies engineered to target the core mechanisms of plaque psoriasis and other dermatologic conditions [4] Product Details - ORKA-002 is administered subcutaneously and has shown superior efficacy in preclinical studies compared to existing therapies that require monthly maintenance dosing [3][6] - Projections indicate that ORKA-002 could have a human half-life of approximately 50 to 75 days, allowing for dosing intervals of once every four months or twice a year [6]